Abiopharma

Oragenics Q2 2025 Shareholder Update

Neogen® Establishes Relationship with Biomatter

SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Oragenics Q2 2025 Shareholder Update

New Form F-4 - BioNTech SE Filed: 2025-08-11 AccNo: 0001193125-25-177520 Size: 2 MB

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

New Form 4 - CUMBERLAND PHARMACEUTICALS INC Filed: 2025-08-11 AccNo: 0001628280-25-039397 Size: 36 KB

RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm

New Form 8-K - Ocugen, Inc. Filed: 2025-08-11 AccNo: 0001104659-25-075956 Size: 757 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Equillium, Inc. Filed: 2025-08-11 AccNo: 0001193125-25-177510 Size: 649 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 10-Q - SONIDA SENIOR LIVING, INC. Filed: 2025-08-11 AccNo: 0001043000-25-000072 Size: 8 MB

New Form 10-Q - UFP TECHNOLOGIES INC Filed: 2025-08-11 AccNo: 0001171843-25-005268 Size: 8 MB

NVO Investors are Reminded of Final Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to AdministerANKTIVA® to Bladder Cancer Patients

New Form 424B5 - Ocugen, Inc. Filed: 2025-08-11 AccNo: 0001104659-25-075953 Size: 470 KB